Related Experiment Video
Updated: Oct 27, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
Topical Oral and Intranasal Antiviral Agents for Coronavirus Disease 2019 (COVID-19)
Victor B Hsue1, Kyohei Itamura1, Arthur W Wu1
1Department of Otolaryngology-Head and Neck Surgery, Cedars Sinai, Los Angeles, CA, USA.
Abstract:
With the largest viral loads in both symptomatic and asymptomatic patients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) present in the oral and nasal cavities, agents that act on these two areas have the potential for large therapeutic and prophylactic benefit. A literature review was conducted to elucidate the possible agents useful in treatment of SARS-CoV-2. These agents were evaluated for their current applications, adverse reactions, their current state of study, and any future considerations in their management of coronavirus disease 2019 (COVID-2019). Our review has found that, while there are many promising agents with proven efficacy in their in-vitro efficacy against SARS-CoV-2, more clinical trials and in-vivo studies, as well as safety trials, must be conducted before these agents can be effectively implemented.
Insights
Agents targeting the oral and nasal cavities show promise for treating and preventing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Further clinical and safety trials are needed to confirm efficacy for coronavirus disease 2019 (COVID-19).
Area of Science:
- Virology
- Infectious Diseases
- Pharmacology
Background:
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viral loads are highest in the oral and nasal cavities.
- Targeting these areas offers potential for therapeutic and prophylactic benefits against coronavirus disease 2019 (COVID-19).
Purpose of the Study:
- To review and evaluate agents with potential efficacy against SARS-CoV-2 in the oral and nasal cavities.
- To assess their current applications, adverse reactions, and stage of research for COVID-19 management.
Main Methods:
- A comprehensive literature review was conducted.
- Agents were evaluated based on in-vitro efficacy, clinical trial status, and safety data.
Main Results:
- Multiple agents demonstrated in-vitro efficacy against SARS-CoV-2.
- Significant potential exists for agents acting on oral and nasal cavities.
Conclusions:
- Promising agents require further clinical trials and in-vivo studies.
- Extensive safety trials are necessary before widespread implementation for COVID-19 treatment and prevention.
More Related Videos
Related Concept Videos
Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Upper Respiratory Drugs: First and Second-Generation Antihistamines
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Upper Respiratory Drugs: Decongestants
Most decongestants are readily available over-the-counter in...
Subviral Agents
Local Anesthetics: Common Agents and Their Applications
Cocaine is an ester of benzoic acid and methylecgogine. It is used to anesthetize and vasoconstrict locally. Currently, it is used primarily for topical applications. It is beneficial for surgeries on the upper respiratory tract, providing anesthesia and shrinking the mucosa. Cocaine in the form of cocaine hydrochloride is...

